Human Immunodeficiency Virus

Medicines in the Human Immunodeficiency Virus category are antiretroviral drugs used to control HIV infection and its effects on the immune system. These medications work by interrupting different stages of the virus’s life cycle to reduce the amount of virus in the blood, help preserve immune function, and lower the risk of HIV-related complications. Popular products encountered in this category include nucleoside agents such as epivir (lamivudine) in its formulations, protease inhibitor-based combinations like kaletra (lopinavir/ritonavir), and non-nucleoside agents such as sustiva (efavirenz). Some formulations, such as certain lamivudine products, have formulations also used in hepatitis B care, reflecting overlap in antiviral activity.

Antiretroviral medications are most commonly used as part of long-term antiretroviral therapy (ART) for people living with HIV. Regimens are generally composed of multiple agents taken together to increase effectiveness and reduce the chance of the virus developing resistance. Beyond chronic treatment, antiretrovirals are sometimes used in specific short-term contexts associated with prevention, such as post-exposure or pre-exposure strategies, and in certain maternal and infant care situations where preventing transmission is a consideration. Use patterns depend on clinical protocols and patient needs.

The category contains several drug classes that act by different mechanisms. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) like lamivudine interfere with the virus’s ability to copy its genetic material. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), exemplified by efavirenz, bind to and inhibit a viral enzyme needed for replication. Protease inhibitors, such as lopinavir boosted with ritonavir in kaletra, prevent maturation of viral particles. Modern portfolios often also include integrase strand transfer inhibitors and entry or fusion inhibitors; many treatment plans combine agents from two or more classes to achieve durable viral suppression.

Medications come in a range of formulations and dosing options intended to fit different needs. Fixed-dose combination pills and single-tablet regimens simplify daily dosing for many adults, while separate tablets or liquid formulations may be used for pediatric patients or when specific dosing adjustments are required. Storage conditions, pill size, dosing frequency and whether a product needs to be taken with food are practical aspects that influence which formulation is chosen. Availability of generic versions can increase access to commonly used agents.

Safety profiles and potential interactions vary across antiretroviral medications. Some agents are associated with side effects such as gastrointestinal upset, changes in cholesterol or glucose metabolism, central nervous system symptoms, or hepatic effects; particular drugs may have more prominent or distinctive adverse effects. Several antiretroviral drugs are involved in clinically important interactions with other prescriptions, over-the-counter products or herbal supplements because they affect or are affected by liver enzymes and drug transport systems. Monitoring of laboratory parameters and clinical response is a routine component of safe use in clinical practice.

When people look for medicines in this category they typically consider the intended clinical purpose, ease of use, formulation suitable for their age and lifestyle, known side-effect patterns and the potential for interactions with other treatments they take. Other common considerations include whether a medicine is part of a recommended regimen, whether fixed-dose combinations are available to reduce pill burden, and whether a product has formulations appropriate for pregnancy or pediatric use. Choice and management of antiretroviral therapy are individualized and guided by healthcare providers, treatment guidelines and patient preferences.